Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319712 | 0.84 | CNR1 (0.44) | CASRCNR1 | |
| SCHEMBL3314526 | 0.83 | CACNA2D1 (0.43) | HPGDGPR139 | |
| SCHEMBL3317794 | 0.81 | CNR1 (0.46) | CASRCNR1HPGD | |
| SCHEMBL3319177 | 0.81 | SOS1 (0.37) | CNR1KMT2AGPR139 | |
| SCHEMBL6169776 | 0.77 | GAA (0.50) | CASRCNR1CYP2D6GAAL3MBTL1 | |
| SCHEMBL3316301 | 0.76 | KDM4E (0.44) | HPGDGAAL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL3317146 | 0.76 | L3MBTL1 (0.42) | GAAL3MBTL1 | |
| SCHEMBL3316633 | 0.74 | SLC6A9 (0.44) | GAAL3MBTL1MEN1KMT2AGPR139 | |
| SCHEMBL3317389 | 0.74 | KIF11 (0.38) | CNR1HPGDMEN1KMT2A | |
| SCHEMBL3317174 | 0.73 | HRH4 (0.39) | CASRGAAL3MBTL1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | CASR 117/4885CNR1 1/4885CYP2D6 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.